Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin versus empagliflozin + linagliptin for atherosclerosis markers in type 2 diabetes
IRCT20241230064218N1Phase 3Completed
- Sponsor
- Aja University of Medical Sciences
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in type 2 diabetes mellitus (T2DM) and atherosclerosis comparing Empagliflozin monotherapy with Empagliflozin + linagliptin combination therapy (2 arms). Primary endpoints: Carotid intima-media thickness and Pericardial fat thickness. Started Jun 2025; status: completed.
02
Drugs
empagliflozinlinagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)atherosclerosis
Beyond the preview
Go deeper on IRCT20241230064218N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241230064218N1.